ArticlePloS one2020

CRISPR/Cas9-targeting of CD40 in hematopoietic stem cells limits immune activation mediated by anti-CD40.

Rui Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.